CANY
NTLA icon

Caxton Associates (New York)’s Intellia Therapeutics NTLA Stock Holding History

Caxton Associates (New York)’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,172
Closed -$375K – 650
2021
Q4 		$375K Buy
+3,172
New +$397K 0.04% 350
2021
Q2 		– Sell
-3,940
Closed -$316K – 565
2021
Q1 		$316K Buy
+3,940
New +$264K 0.03% 263

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Caxton Associates (New York)'s NTLA Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 3,172 shares — an estimated $375K sold.

Caxton Associates (New York) first reported a position in NTLA in Q1 2021 and held it in 2 quarters. The position peaked at $375K in Q4 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 3,172 Intellia Therapeutics shares in Q1 2022, an estimated $375K.
  • Caxton Associates (New York) first reported a position in Intellia Therapeutics in Q1 2021 and held it in 2 quarters.
  • Caxton Associates (New York)'s Intellia Therapeutics position peaked at $375K in Q4 2021.
  • 348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.